Theratechnologies Resumes Distribution of EGRIFTA SV®
MONTREAL, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ('Theratechnologies' or the 'Company') (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care, today announced that it has resumed distribution of EGRIFTA SV® (tesamorelin for injection), following correspondence from the U.S. Food and Drug Administration (FDA) that allows the Company to release two recently manufactured batches of EGRIFTA SV®. The product is ready for immediate shipment to network pharmacies.
'We remain committed to providing EGRIFTA SV® to people with HIV and we truly appreciate the FDA's collaboration to get the treatment back to the patients who rely on it,' said Christian Marsolais, PhD, Senior Vice President and Chief Medical Officer at Theratechnologies.
Review of the Company's Prior Approval Supplement by the FDA is ongoing with an action goal date of April 18, 2025.
EGRIFTA SV® is distributed in the United States only.
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and X.
Forward-Looking Information
This press release contains forward-looking statements and forward-looking information (collectively, the 'Forward-Looking Statements') within the meaning of applicable securities laws, that are based on management's beliefs and assumptions and on information currently available to it. You can identify forward-looking statements by terms such as 'may', 'will', 'should', 'could', 'promising', 'would', 'outlook', 'believe', 'plan', 'envisage', 'anticipate', 'expect' and 'estimate', or the negatives of these terms, or variations of them.
The Forward-Looking Statements contained in this press release include, but are not limited to, statements regarding: (i) the review of the Prior Approval Supplement (PAS) within the timelines announced herein; and (ii) the provision of EGRIFTA SV® to people with HIV. Although the Forward-Looking Statements contained in this press release are based upon what the Company believes are reasonable assumptions in light of the information currently available, investors are cautioned against placing undue reliance on these statements since actual results may vary from the Forward-Looking Statements contained in this press release. Certain assumptions made in preparing the Forward-Looking Statements include that: (i) the PAS will be approved by the FDA; (ii) the review of the PAS will be completed within the timelines disclosed herein; (iii) current market demand for EGRIFTA SV® has not been adversely impacted by the drug shortage; and (iv) the Company's third party manufacturer will be able to continue the manufacture of EGRIFTA SV® to meet patients demand . Forward-Looking Statements assumptions are subject to a number of risks and uncertainties, many of which are beyond the Company's control, that could cause actual results to differ materially from those that are disclosed in or implied by such Forward-Looking Statements. These risks and uncertainties include, but are not limited to: (i) FDA's review of the PAS not being completed by April 18, 2025; (ii) non-approval of the PAS; (iii) issuance of questions as part of the PAS review by the FDA resulting in delays in completing the PAS review and resulting in delays beyond April 18, 2025, to release additional batches of EGRIFTA SV®, if need be; (iv) issuance of a complete response letter following the filing of the PAS as a result of the manufacturing site being classified as Official Action Indicated preventing the Company from releasing additional batches of EGRIFTA SV®, unless new authorizations similar to the one announced herein are obtained from the FDA; and (v) a decrease in demand for EGRIFTA SV® due to the recent shortage adversely impacting the resumption of the commercialization of EGRIFTA SV®;. The Company refers current and potential investors to the 'Risk Factors' section of the Company's Form 20-F dated February 21, 2024 available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov under Theratechnologies' public filings. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-Looking Statements reflect current expectations regarding future events and speak only as of the date of this press release and represent the Company's expectations as of that date.
The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.
Contacts:
Media inquiries:Julie SchneidermanSenior Director, Communications & Corporate Affairscommunications@theratech.com1-514-336-7800
Investor inquiries:Joanne ChoiSenior Director, Investor Relationsjchoi@theratech.com1-551-261-0401
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Super Micro Unleashes 30+ Nvidia Blackwell AI Systems Across Europe
June 12 - Super Micro Computer (NASDAQ:SMCI) has rolled out over 30 new enterprise AI solutions in Europe built on Nvidia's (NASDAQ:NVDA) Blackwell chip architecture, aiming to speed up deployment of AI infrastructure across the region. Warning! GuruFocus has detected 4 Warning Signs with NVDA. The expanded portfolio includes systems powered by the air- and liquid-cooled NVIDIA HGX B200, liquid-cooled NVIDIA GB200 NVL72, and RTX PRO 6000 Blackwell Server Edition GPUs. The systems are designed to support enterprise-grade AI factories across varied environments, from data centers to edge networks. Supermicro said its latest offerings are optimized to deliver faster deployment timelines and energy-efficient performance through its advanced liquid cooling systems and integration with Nvidia technologies. The company has begun taking orders for the new GPU-based systems, which are available in multiple configurations to accommodate a broad range of enterprise needs. CEO Charles Liang said Supermicro's early access to Nvidia's Blackwell architecture and its global manufacturing capacity position it well to support rising demand for AI infrastructure in the region. Based on the one year price targets offered by 15 analysts, the average target price for Super Micro Computer Inc is $40.00 with a high estimate of $70.00 and a low estimate of $15.00. The average target implies a downside of -7.44% from the current price of $43.21. Based on GuruFocus estimates, the estimated GF Value for Super Micro Computer Inc in one year is $68.35, suggesting a upside of +58.18% from the current price of $43.21. This article first appeared on GuruFocus.
Yahoo
11 minutes ago
- Yahoo
NNBR Q1 Earnings Call: Revenue Falls Short, Management Emphasizes Cost Cuts and New Business Pipeline
Industrial components supplier NN (NASDAQ:NNBR) missed Wall Street's revenue expectations in Q1 CY2025, with sales falling 12.8% year on year to $105.7 million. The company's full-year revenue guidance of $445 million at the midpoint came in 2% below analysts' estimates. Its non-GAAP loss of $0.03 per share was in line with analysts' consensus estimates. Is now the time to buy NNBR? Find out in our full research report (it's free). Revenue: $105.7 million vs analyst estimates of $109.7 million (12.8% year-on-year decline, 3.7% miss) Adjusted EBITDA: $10.58 million vs analyst estimates of $11.73 million (10% margin, 9.8% miss) The company dropped its revenue guidance for the full year to $445 million at the midpoint from $465 million, a 4.3% decrease EBITDA guidance for the full year is $58 million at the midpoint, above analyst estimates of $53.16 million Operating Margin: -4.5%, in line with the same quarter last year Market Capitalization: $109 million NN's first quarter performance was shaped by ongoing softness in its core automotive markets and broader industrial demand uncertainty. CEO Harold Bevis highlighted that sales lagged internal expectations, particularly among global automotive customers, with management shifting its business development efforts to immediate, profitable ramp-up sales to compensate. The company's new business program—nicknamed PIGS (Profitable Immediate Growth Strategy)—was a focal point, as management stated it successfully secured $55 million in new program wins ramping up throughout the year. Operational cost reductions, including a 16% workforce reduction since mid-2023, were a key lever to offset market headwinds, with management indicating these actions would support profit improvement in the coming quarters. Looking forward, NN's updated full-year guidance centers on a combination of new business launches, ongoing cost reductions, and working capital improvements. Management reiterated its confidence in hitting EBITDA and free cash flow targets, underpinned by what Bevis described as significant open capacity and a large pipeline of new business opportunities—particularly in industrial and medical segments. The company acknowledged persistent economic uncertainty and tariffs as factors influencing its revenue forecast, but expects its immediate ramp-up wins to partially offset base business weakness. CFO Chris Bohnert noted, 'Our Q1 results have NN on pace to achieve full-year guidance, and we anticipate maintaining this pace through 2025,' while also warning that market conditions could push results toward the lower end of the expected range. Management attributed first quarter results to a combination of softening base business demand and successful execution of new business programs, while emphasizing aggressive cost reduction and operational changes. Automotive demand remains volatile: Management cited lower volumes from global automotive customers, which make up 40% of sales, as a primary factor behind the quarter's weaker demand. The company noted a global slowdown in the transition from internal combustion engine (ICE) to electric vehicles (EV), leading to a more balanced market that leverages NN's existing capabilities. PIGS program drives new wins: The Profitable Immediate Growth Strategy (PIGS) was highlighted as a key initiative, with 120 new programs worth $55 million in annualized sales set to ramp up during 2025. Management said these wins are helping offset softness in legacy business lines and are expected to significantly impact results in the second half of the year. Cost reduction accelerates: The company completed a 16% reduction in its workforce since Q2 2023, with further headcount alignment and cost-cutting underway. Management stated that these initiatives are already improving EBITDA per salaried employee and will continue to support profit margins. Capacity utilization supports growth: NN operated most plants on a single shift, leaving substantial open capacity. This allows the company to pursue new business opportunities without significant capital expenditure, supporting both near- and long-term growth objectives. Transformation progress continues: Management reported its multi-year transformation plan is roughly 70% complete, including enhancements to leadership, plant optimization, and the exit of unprofitable business lines. This, paired with improved working capital efficiency, is positioned as a foundation for future margin improvement. NN's outlook is shaped by new business launches, ongoing cost actions, and uncertain demand trends in core markets. New business ramp-up timing: Management expects approximately half of the $55 million in new program wins to begin contributing meaningfully in the second half of 2025, with remaining wins phased in over the next three to nine months. The timing depends on customer-driven ramp schedules and certification processes, especially in medical and industrial segments. Cost savings execution: The $15 million cost reduction target for 2025 is expected to be mostly evenly distributed throughout the year, with some actions back-end loaded. These savings are intended to counteract pressure from lower base business volumes and support targeted EBITDA margins. Tariff and market uncertainty: Management acknowledged that tariffs and ongoing economic unpredictability continue to affect both quoting activity and customer order patterns, particularly in automotive. While NN is pursuing reshoring and tariff-driven requests for quotes, the company remains selective and cautious about new automotive business requiring significant capital investments. In the coming quarters, the StockStory team will be watching (1) the pace and profitability of new business program ramp-ups, particularly in medical and industrial segments; (2) further progress on cost reduction initiatives and their effect on margins; and (3) updates on plant optimization, including potential consolidations. Execution of tariff-driven opportunities and the company's ability to improve working capital efficiency will also be closely monitored. NN currently trades at a forward P/E ratio of 324.3×. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it's free). Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio
Yahoo
11 minutes ago
- Yahoo
Top Stock Movers Now: Oracle, Boeing, CureVac, and More
U.S. equities were mixed and little changed at midday as a second inflation report this week came in lower than anticipated. Demand for Oracle's cloud computing demand sent shares higher. Shares of Boeing tumbled after one of its 787 planes crashed in India.U.S. equities were mixed and little changed at midday as another key measure of inflation, the Producer Price Index (PPI), came in lower than expected. The S&P 500 and Nasdaq advanced, while the Dow Jones Industrial Average was lower. Oracle (ORCL) was the best-performing stock in the S&P 500 after the computer software manufacturer beat profit and sales estimates and said it sees demand for its cloud infrastructure products soaring. Shares of CureVac (CVAC) took off after the biotech company was purchased by COVID-19 vaccine maker and fellow German firm BioNTech (BNTX) in an all-stock deal valued at about $1.25 billion. BioNTech American Depositary Receipts (ADRs) were little changed. Shares of Newmont (NEM) and rival gold miners gained along with the price of the precious metal, which traded around at its highest level in more than a month on optimism about interest rate cuts. Boeing (BA) shares slumped after one of the plane maker's 787 passenger jets crashed in India, killing more than 200 people. Shares of Tommy Bahama owner Oxford Industries (OXM) sank when the apparel maker cut its guidance and warned tumbling consumer sentiment and tariffs will hurt results. GameStop (GME) shares plunged after the video-game retailer announced it would offer $1.75 billion in convertible bonds for sale. Oil futures were little changed. The yield on the 10-year Treasury note declined. The U.S. dollar lost ground to the euro, pound, and yen. Most major cryptocurrencies traded lower. Read the original article on Investopedia
